Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:13:31 EDT Tue 26 Aug 2025
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - https://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q0.19.45·9.480.59.4556+0.05560.628.02522529.39  9.52  9.337414.4405  4.930109:52:5407:3015 min RT 2¢

Recent Trades - Last 10 of 252
Time ETExPriceChangeVolume
09:53:02Q9.4650.06517
09:52:54Q9.45560.0556100
09:52:46Q9.450.051
09:52:46Q9.450.051
09:52:35Q9.460.06996
09:52:35Q9.460.064
09:52:26Q9.45330.053370
09:52:19Q9.480.081
09:52:01Q9.46620.0662500
09:51:50Q9.4650.06538

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-08-26 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
2025-08-20 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
2025-08-12 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
2025-08-05 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
2025-07-31 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
2025-05-14 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate at Upcoming Healthcare Conferences
2025-05-13 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
2025-05-06 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
2025-05-01 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX(TM)3-71 for the Treatment of Schizophrenia
2025-04-30 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate in The Citizens Life Sciences Conference
2025-04-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
2025-04-21 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
2025-04-05 11:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
2025-03-31 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
2025-02-24 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
2025-02-12 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
2025-02-05 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
2025-01-27 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX(TM)2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
2025-01-15 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease
2025-01-13 07:30U:AVXLNews ReleaseNew Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients